Mateo Marin-Cuartas

Dr. Mateo Marin-Cuartas


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
Fabien PrazFabien Praz
Fabien Praz
MBMichael Borger
Michael Borger
JLJonas Lanz
Jonas Lanz
MMMateo Marin-Cuartas
Mateo Marin-Cuartas
AAAna Abreu
Ana Abreu
NMNarain Moorjani
Narain Moorjani

2 August 2025 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
Fabien PrazFabien Praz
Fabien Praz
MBMichael A Borger
Michael A Borger
JLJonas Lanz
Jonas Lanz
MMMateo Marin-Cuartas
Mateo Marin-Cuartas
AAAna Abreu
Ana Abreu
EGESC/EACTS Scientific Document Group
ESC/EACTS Scientific Document Group

1 November 2019 in Annals of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
PDPiroze M. Davierwala
Piroze M. Davierwala
MMMateo Marin-Cuartas
Mateo Marin-Cuartas
MMMartin Misfeld
Martin Misfeld
MBMichael A. Borger
Michael A. Borger
Establishment of the Heart Team concept in the field of cardiovascular medicine has resulted in quality improvement in the management of heart valve disease and heart failure. Similarly, the concept of an Endocarditis Team would be important in improving outcomes in patients with infective endocarditis (IE), given it is an uncommon clinical entity with general practitioners and low-volume centers lacking sufficient experience in its management. A multidisciplinary approach can substantially reduce the still unacceptably high morbidity and mortality in patients with IE, as it allows early diagnosis and appropriate comprehensive management. Decision-making within the Endocarditis Team must follow a standard protocol that is based on current clinical guidelines for the management of IE. If surgery is indicated, it is best performed sooner than later in most instances. Communication between referring hospitals and reference centers with an established Endocarditis Team must be smooth and definite protocols for transfer to experienced endocarditis centers with surgical facilities is essential. Follow-up and outpatient care following hospital discharge is crucial due to the possibility of residual infection and risk of development of recurrent endocarditis or heart failure, particularly within the first 2 years. Patient and health-care provider education is the mainstay for the accurate implementation of the Endocarditis Team concept. The following Keynote Lecture offers an overview of the current literature supporting the multidisciplinary management of IE and addresses multiple aspects related to the Endocarditis Team, highlighting its importance and necessity for the comprehensive treatment of this complex disease.

1 November 2017 in Progress in Cardiovascular Diseases
Verified
Journal Article
Open access
MMMateo Marin-Cuartas
Mateo Marin-Cuartas
HJHoda Javadikasgari
Hoda Javadikasgari
BPBettina Pfannmueller
Bettina Pfannmueller
JSJoerg Seeburger
Joerg Seeburger
AGA. Marc Gillinov
A. Marc Gillinov
MBMichael Borger
Michael Borger
Robotic and minimally invasive mitral valve (MV) procedures have been performed with increasing frequency over time. These alternatives offer similar efficacy to that achieved via standard median sternotomy, particularly in large volume centers, along with low perioperative morbidity and mortality rates. Moreover, patient acceptance is oftentimes increased due to less postoperative pain and shorter recovery times, as well as superior cosmetic results. However, these techniques are technically complex and associated with a significant learning curve. The following review offers an overview of the most relevant aspects related to minimally invasive and robotic MV repair. Although these techniques are well established in referral centers, future innovations should concentrate on decreasing complexity and improving reproducibility of these procedures.

7 May 2020 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDPiroze M Davierwala
Piroze M Davierwala
MMMateo Marin-Cuartas
Mateo Marin-Cuartas
MMMartin Misfeld
Martin Misfeld
SDSalil V Deo
Salil V Deo
SLSven Lehmann
Sven Lehmann
FBFarhad Bakhtiary
Farhad Bakhtiary
OBJECTIVES: Destruction of the intervalvular fibrous body (IFB) due to infective endocarditis (IE) warrants a complex operation involving radical debridement of all infected tissue, followed by double valve replacement (aortic and mitral valve replacement) with patch reconstruction of the IFB. This study assesses the 5-year outcomes in patients undergoing this complex procedure for treatment of double valve IE with IFB involvement. METHODS: A total of 127 consecutive patients underwent double valve replacement with reconstruction of the IFB for active complex IE between January 1999 and December 2018. Primary outcomes were 3-year and 5-year survival, as well as 5-year freedom from reoperation. RESULTS: Patients’ mean age was 65.3 ± 12.9 years. Preoperative cardiogenic shock and sepsis were present in 17.3% and 18.9%, respectively. The majority of patients (81.3%) had undergone previous cardiac surgery. Overall, 30-day and 90-day mortality rates were 28.3% and 37.0%, respectively. The 3- and 5-year survival rates for all patients were 45.3 ± 5.1% and 41.8 ± 5.8%, and for those who survived the first 90 postoperative days 75.8 ± 6.1% and 70.0 ± 8.0%, respectively. The overall 5-year freedom from reoperation was 85.1 ± 5.7%. Preoperative predictors for 30-day mortality were Staphylococcus aureus [odds ratio (OR) 1.65; P = 0.04] and left ventricular ejection fraction (LVEF) <35% (OR 12.06; P = 0.03), for 90-day mortality acute kidney injury requiring dialysis (OR 6.2; P = 0.02) and LVEF <35% (OR 9.66; P = 0.03) and for long-term mortality cardiogenic shock (hazard ratio 2.46; P = 0.01). CONCLUSIONS: Double valve replacement with reconstruction of the IFB in patients with complex IE is a challenging operation associated with high morbidity and mortality, particularly in the first 90 days after surgery. Survival and freedom from reoperation rates are acceptable thereafter, particularly considering the severity of disease and complex surgery.

4 January 2023 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MMMartin Misfeld
Martin Misfeld
MMMateo Marin-Cuartas
Mateo Marin-Cuartas
PRPaulina Ramirez
Paulina Ramirez
KWKatharina Wehrmann
Katharina Wehrmann
KRKatharina Renatus
Katharina Renatus
CEChristian D. Etz
Christian D. Etz